Clinical Trial

NervGen Pharma to Present at the Virtual Life Science Investor Forum

Vancouver, British Columbia--(Newsfile Corp. - March 5, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

10 months ago

Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture

Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous…

10 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics…

10 months ago

Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results

FY 2024 revenue of $228.4 million, in-line with company guidanceCommercial Cell & Gene Therapy revenue rose to $26 million in…

10 months ago

AI in Remote Patient Monitoring (RPM) Market worth $8,438.5 million by 2030 with 27.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., March 4, 2025 /PRNewswire/ -- The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million…

10 months ago

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

BERWYN, Pa.  and DUBLIN, March 4, 2025 /PRNewswire/ -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and…

10 months ago

Volition’s Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development…

10 months ago

BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells

Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest's Future Olive Cell Product…

10 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif. and LOS ANGELES,…

10 months ago

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO,…

10 months ago